Home / Research library / Cerebrolysin
Cerebrolysin: molecular data, studies & sources
Cerebrolysin is catalogued here as an identity or preparation requiring extra specification. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
Molecular record not yet resolved
Cerebrolysin is a peptide and amino-acid preparation, not one discrete molecule. Clinical findings concern the studied preparation.
MF: not assigned · MW: not assigned · Structure: not assigned
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Cerebrolysin as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
40 registered studies matched, 8 currently active or recruiting, 3 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 4 · 13Phase 3 · 7Phase 2 · 9Phase 1 · 1Early phase 1 · 1Not applicable · 9
- By registry status
- Completed · 18Unknown · 10Not Yet Recruiting · 3Recruiting · 3Terminated · 3Active Not Recruiting · 1Enrolling By Invitation · 1Withdrawn · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic StrokeNCT07846488 · start 2026-12-01 · primary completion 2028-06-30 | Not applicableNot Yet Recruiting | Ischemic Stroke · Hemiplegia · Neurogenic Dysphagia | National Hospital of Acupuncture, Vietnam440 participants |
| Cerebrolysin After Reperfusion in Extended-window EndoVascular ThrombectomyNCT06339411 · start 2026-09-01 · primary completion 2029-12-31 | Phase 2Not Yet Recruiting | Acute Ischemic Stroke | Chang Gung Memorial Hospital100 participants |
| Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point TrialNCT06899464 · start 2025-10-01 · primary completion 2027-01-01 | Phase 4Not Yet Recruiting | Intracerebral Hemorrhage · Hemorrhagic Stroke, Intracerebral · Hemorrhagic Stroke · Stroke | Cardinal Stefan Wyszynski University30 participants |
| Cerebrolysin in Early Stroke Rehabilitation - Tertiary StudyNCT07043686 · start 2025-06-13 · primary completion 2027-07-15 | Not applicableRecruiting | Ischemic Stroke, Acute · Rehabilitation Outcome · Cerebrolysin | University Medical Centre Ljubljana30 participants |
| Cerebrolysin in Critically Ill Patients With DeliriumNCT06677502 · start 2024-01-01 · primary completion 2025-06-30 | Not applicableEnrolling By Invitation | Cognitive Impairment | Medical University of Lublin500 participants |
| CERebrolysin In CADASILNCT05755997 · start 2023-11-29 · primary completion 2026-03-31 | Phase 2Active Not Recruiting | Cadasil | Ever Neuro Pharma GmbH30 participants |
| Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's PalsyNCT05821075 · start 2023-08-24 · primary completion 2026-01 | Phase 1 / Phase 2Recruiting | Bell Palsy | October 6 University90 participants |
| Efficacy and Safety of Cerebrolysin on Prolonged Disorders of ConsciousnessNCT04427241 · start 2023-06-01 · primary completion 2026-09-30 | Phase 4Recruiting | Disorder of Consciousness · Hemorrhagic Stroke | Konkuk University Medical Center12 participants |
| Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery OcclusionNCT06489925 · start 2024-07 · primary completion 2025-05 | Early phase 1Unknown | Basilar Artery Occlusion · Posterior Circulation Brain Infarction | University Hospital Sestre Milosrdnice20 participants |
| A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)NCT06070753 · start 2023-10-01 · primary completion 2024-06-30 | Not applicableUnknown | Acute Ischemic Stroke | Shaare Zedek Medical Center30 participants |
Show 30 more registered studies
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICUNCT06052787 · start 2023-09-01 · primary completion 2025-05-30 | Phase 3Completed | Traumatic Brain Injury | Ain Shams University150 participants |
| Cerebrolysin in Prevention of Postoperative Delirium in Cardiac SurgeryNCT05864677 · start 2023-01-15 · primary completion 2024-06-30 | Not applicableUnknown | Neurocognitive Disorders · Surgery-Complications · Critical Illness · Brain Damage · Cardiac Disease | Medical University of Lublin100 participants |
| CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic StrokeNCT06078215 · start 2023-01-10 · primary completion 2025-01-31 | Phase 4Unknown | Acute Ischemic Stroke | Poznan University of Medical Sciences350 participants |
| Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic StrokeNCT06273020 · start 2022-11-17 · primary completion 2024-11 | Phase 4Unknown | Ischemic Stroke, Acute · Diabetes Mellitus, Type 2 · Blood Brain Barrier | Hospital Universitario Dr. Jose E. Gonzalez60 participants |
| Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 VariantsNCT06208540 · start 2021-08-30 · primary completion 2024-04-30 | Phase 4Completed | Post-covid-19 Persistent Smell and Taste Disorders | Sherifa Ahmed Hamed160 participants |
| IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokENCT04124367 · start 2021-06-25 · primary completion 2022-03-21 | Phase 2TerminatedWhy stopped: for strategic and pandemic reasons | Chronic Stroke · Subacute Stroke | Ever Neuro Pharma GmbH4 participants |
| Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled StudyNCT04913831 · start 2021-06 · primary completion 2024-03 | Phase 4Unknown | Stroke | Yonsei University30 participants |
| Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVTNCT05124353 · start 2021-04-27 · primary completion 2023-04-01 | Phase 2 / Phase 3Unknown | Stroke, Acute, Ischemic | Pomeranian Medical University Szczecin100 participants |
| Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.NCT04904341 · start 2021-01-01 · primary completion 2023-12-31 | Phase 3Unknown | Stroke, Ischemic · Stroke, Acute · Stroke Sequelae | Military Institute od Medicine National Research Institute50 participants |
| Cerebrolycin for Treatment of Covid-related Anosmia and AgeusiaNCT04830943 · start 2020-08-01 · primary completion 2021-09-30 | Phase 3Completed | Covid19 Related Anosmia and Aguesia | Assiut University250 participants |
| Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain InjuryNCT05807503 · start 2020-02-01 · primary completion 2022-10-31 | Not applicableCompleted | TBI (Traumatic Brain Injury) | Pomeranian Medical University Szczecin56 participants |
| Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative EffectivenessNCT03480698 · start 2018-04-24 · primary completion 2024-04-30 | Not applicableCompleted | Acute Ischemic Stroke | Ever Neuro Pharma GmbH1851 participants |
| the Effect of Cerebrolysin on Physical and Mental Functions of Down SyndromeNCT04751136 · start 2016-09-30 · primary completion 2019-02-28 | Phase 2Completed | Down Syndrome | Mansoura University Children Hospital64 participants |
| Cerebrolysin and Neurodevelopment in Preterm InfantsNCT03506841 · start 2016-06 · primary completion 2019-06 | Phase 1Completed | Infant Development · Cerebral Palsy · Preterm Infant | Mansoura University Children Hospital60 participants |
| Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in StrokeNCT02768571 · start 2016-03-14 · primary completion 2019-02-14 | Phase 4Completed | Stroke | Samsung Medical Center80 participants |
| Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-ArmNCT02581371 · start 2015-02 · primary completion 2017-02 | Phase 4Unknown | Ischemic Stroke | Clinical Institute of the Brain, Russia30 participants |
| Hair Repigmentation During Cerebrolysin TherapyNCT05288465 · start 2014-06-02 · primary completion 2015-12-07 | Not applicableCompleted | Hair Problems | Universidad Autonoma de Nuevo Leon5 participants |
| Cerebrolysin REGistry Study in StrokeNCT02541227 · start 2014-05 · primary completion 2017-12 | Not applicableTerminatedWhy stopped: The goal to match 1000 patients per group could not be achieved with reasonable effort and in reasonable time. | Ischemic Stroke | Ever Neuro Pharma GmbH1823 participants |
| Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral PalsyNCT02116348 · start 2014-04 · primary completion 2016-04 | Phase 2Unknown | Cerebral Palsy Children · Children With Traumatic Brain Injury · Mental Handicap · Delayed Speech Development | Ain Shams University100 participants |
| Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid HemorrhageNCT01787123 · start 2013-12-01 · primary completion 2019-01-01 | Phase 2 / Phase 3Completed | Subarachnoid Hemorrhage · Intracranial Aneurysm · Delayed Cerebral Ischemia · Delayed Ischemic Neurological Deficit | Kwong Wah Hospital50 participants |
| The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and NeurorecoveryNCT01606111 · start 2013-09 · primary completion 2015-07 | Phase 4TerminatedWhy stopped: Poor patient recruitment | Traumatic Brain Injury | Ever Neuro Pharma GmbH46 participants |
| Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic EncephalopathyNCT01059461 · start 2011-03 · primary completion 2013-09 | Phase 2Completed | Hypoxic-Ischemic Encephalopathy | Sahar M.A. Hassanein, MD40 participants |
| Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.NCT01388738 · start 2011-01 · primary completion 2011-10 | Phase 3Completed | Stroke | Clinical Institute of the Brain, Russia30 participants |
| Effects of Cerebrolysin on Motor Recovery in Patients With Subacute StrokeNCT01996761 · start 2011-01 · primary completion 2014-01 | Phase 4Completed | Cerebrolysin | Samsung Medical Center71 participants |
| Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic StrokeNCT02149875 · start 2010-01 · primary completion 2010-05 | Phase 1 / Phase 2CompletedResults posted 2016-05-18 | Acute Cerebral Stroke Within 12 Hours for the First Time | Shanghai 6th People's Hospital84 participants |
| A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular DementiaNCT00947531 · start 2006-10 | Phase 4CompletedResults posted 2009-07-28 | Vascular Dementia | Ever Neuro Pharma GmbH242 participants |
| The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic StrokeNCT00868283 · start 2006-09 · primary completion 2010-10 | Phase 4Completed | Ischemic Stroke | Ever Neuro Pharma GmbH1071 participants |
| Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric StrokeNCT00840671 · start 2005-10 · primary completion 2008-03 | Phase 3Completed | Stroke | Ever Neuro Pharma GmbH119 participants |
| Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's DiseaseNCT00911807 · start 2004-10 · primary completion 2008-04 | Phase 2CompletedResults posted 2009-06-02 | Alzheimer Disease | Ever Neuro Pharma GmbH217 participants |
| Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)NCT01822951 · primary completion 2016-09 | Phase 4Withdrawn | Alzheimer Disease | Ever Neuro Pharma GmbHEnrollment not listed |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Cerebrolysin, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
Panisset M, Gauthier S, Moessler H et al. · Journal of neural transmission (Vienna, Austria : 1996) · 2002
PMID 12111446 · DOI: 10.1007/s007020200092
- Human study · PubMed trial index Compound given to participants
Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy.
Sharma A, Agrawal H, Naseem A et al. · Spine · 2023
PMID 36730671 · DOI: 10.1097/BRS.0000000000004542
- Human study · PubMed trial index Compound given to participants
Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study.
Khasanova DR, Kalinin MN · BMC neurology · 2023
PMID 36973684 · DOI: 10.1186/s12883-023-03159-w
- Human study · PubMed trial index Compound given to participants
The Effect of Cerebrolysin on the Predictive Value of Baseline Prognostic Risk Score in Moderate and Severe Traumatic Brain Injury.
Birle C, Slavoaca D, Muresanu I et al. · Journal of medicine and life · 2020
PMID 33072197 · DOI: 10.25122/jml-2020-0146
- Human study · PubMed trial index Compound given to participants
Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke.
Bajenaru O, Tiu C, Moessler H et al. · Journal of medicine and life · 2010
PMID 20968198
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
Cerebrolysin for acute ischaemic stroke.
Ziganshina LE, Abakumova T, Vernay L et al. · The Cochrane database of systematic reviews · 2017
PMID 28430363 · DOI: 10.1002/14651858.CD007026.pub5
- Review · secondary evidence
Cerebrolysin for vascular dementia.
Cui S, Chen N, Yang M et al. · The Cochrane database of systematic reviews · 2019
PMID 31710397 · DOI: 10.1002/14651858.CD008900.pub3
Cerebrolysin supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Cerebrolysin for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Cenexa LabsUSD | 60mg Vial1 recorded offers | 60mg Vial · $62.99Checked Nov 6, 2026Supplier listing, Cerebrolysin 60mg Vial, Cenexa Labs, opens in a new tab |
Reference sources & further reading
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Adalank Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax 1032 Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Agomelatine Powder
C15H17NO2
243.30 g/mol · PubChem CID 82148
8 selected publications · 5 human intervention studies · 19 registered trials
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Dihexa
C27H44N4O5
504.7 g/mol · PubChem CID 129010512
2 selected publications · 0 human intervention studies
Fasoracetam Powder
C10H16N2O2
196.25 g/mol · PubChem CID 198695
3 selected publications · 1 human intervention study · 6 registered trials
Small molecule · highest stage: Phase 2